CRTPF News and Press, Cardiol Therapeutics

Oakville, Ontario--(Newsfile Corp. - August 9, 2021) - Cardiol Therapeutics Inc. ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced to...

Oakville, Ontario--(Newsfile Corp. - July 7, 2021) - Cardiol Therapeutics Inc. ( TSX: CRDL ) ( OTCQX: CRTPF ) ( FSE: CT9 ) (" Cardiol " or the " Company "), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardio...

Oakville, Ontario--(Newsfile Corp. - June 30, 2021) - Cardiol Therapeutics Inc. ( TSX: CRDL ) ( OTCQX: CRTPF ) ( FSE: CT9 ) (" Cardiol " or the " Company "), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardi...

Oakville, Ontario--(Newsfile Corp. - June 28, 2021) - Cardiol Therapeutics Inc. ( TSX: CRDL ) ( OTCQX: CRTPF ) ( FSE: CT9 ) (" Cardiol " or the " Company "), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardi...

Palm Beach, FL – June 15, 2021 – The modern psychedelic renaissance has empirically proven that psychedelic drugs are going to revolutionize mental health treatment. Before these incredibly promising medicines can get to the people who need them the most, they must pass throug...

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease Oakville, Ontario--(Newsfile Corp. - April 28, 2021) -  Cardiol Therapeutics Inc. ( TSX: CRDL )...

Cardiol Therapeutics (CRTPF) posts positive topline results from a Phase I single and multiple ascending dose clinical trial of CardiolRx, an oral cannabidiol formulation being developed for the treatment of acute and chronic inflammation associated with heart disease.The Phase I trial was a ...

Results expected to support the Company's plans to file an IND application with the FDA for a Phase II international trial in acute myocarditis Oakville, Ontario--(Newsfile Corp. - April 12, 2021) - Cardiol Therapeutics Inc. ( TSX: CRDL ) ( OTCQX: CRTPF ) ( FSE: CT9 ) ( "Cardiol" or ...

Oakville, Ontario--(Newsfile Corp. - April 1, 2021) - Cardiol Therapeutics Inc. ( TSX: CRDL ) ( OTCQX: CRTPF ) ( FSE: CT9 ) (" Cardiol " or the " Company "), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of car...

Cardiol Therapeutics (CRTPF) appointed 30-years industry veteran Dr. Andrew Hamer as chief medical officer, effective immediately, leading the R&D of the company's clinical-stage products and also guiding the development of additional novel therapeutics in the company'...